The Leukemia & Lymphoma Society (LLS) today announced it has committed $40.3 million in new research investments to advance the most promising blood cancer science at leading academic and medical centers around the world, including Dana-Farber Cancer Institute in Boston; Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center in New York; MD Anderson Cancer Center in Houston; Fondazione Centro San Raffaele in Milan; and South Australian Health & Medical Research Institute in Adelaide.
This $40.3 million investment, comprised of 75 new research grants in LLS’s portfolio of 300 projects, will fund a diverse array of research to find better treatments and cures for patients with leukemia, lymphoma, myeloma and other blood cancers.
To view the multimedia release go to:
http://www.multivu.com/players/English/7554855-lls-invests-millions-new-research-treatment-cures/
All of us will experience hair loss as we age. The rate at which we do will dependent on what you put on our hair and how you treat it. Do you treat it as an asset, or it just something that gets in your way? Well, treat your hair like a Queen or King, and the longer you will have it.
1 in 3 women will notice hair thinning in her lifetime, and it can start as early as her 20’s. Today, the hair regrowth category leader, ROGAINE® Brand, announced the official launch to market of Women's ROGAINE® 5% Minoxidil Topical Aerosol, the first and only FDA-approved, once-daily use treatment for Female Pattern Hair Loss containing 5 percent minoxidil in an elegant foam formula. Minoxidil is the only topical ingredient FDA-approved to help regrow hair.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7368851-introducing-women-s-rogaine-5-percent-minoxidil-topical-aerosol-fda-approved/
https://tinyurl.com/y7x2j3na Tinnitus: Do You Want The Ringing in Your Ears to Stop?
Recently, my sister asked me if I knew of any natural remedy for ringing in the ears. She said the ringing was keeping her awake at night. And, her daughter has the same problem. Her daughter had to listen to a loud radio to mask the ringing so that she could concentrate on doing her job.
Results from two national surveys of patients receiving chemotherapy and pharmacists, conducted by the Hematology/Oncology Pharmacy Association (HOPA) in collaboration with Eisai Inc.,* found that 83% of patients receiving chemotherapy who have experienced chemotherapy-induced nausea and vomiting (CINV) believe it is a side effect with which they must live. Results also showed that 95% of cancer patients surveyed believe that CINV has, at some point, had an impact on their daily lives. These national surveys are part of the Time to Talk CINV™ campaign, which aims to increase awareness among patients and caregivers about CINV prevention and the importance of speaking with their pharmacist and full healthcare team about this often preventable side effect.
“The survey results underscore the confusion patients who are undergoing chemotherapy have about CINV and the need for them to understand that there are ways to manage their symptoms so that they do not have to needlessly suffer with CINV,” said Scott Soefje, PharmD, MBA, BCOP, President, Hematology/Oncology Pharmacy Association (HOPA) and Director of Pharmacy at the University Medical Center Brackenridge in Austin, TX. “It is imperative that patients discuss CINV prevention early in treatment and with all members of the health care team, including pharmacists.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7560331-time-to-talk-cinv/
Summit Homes, a Berkshire Hathaway subsidiary through Clayton Properties Group, presented St. Jude Children’s Research Hospital representatives a check for $718,000 following the sale of the builder’s 2017 St. Jude Dream Home Showplace.
Summit Homes, the largest new home builder in Kansas City, built the 2017 St. Jude Dream Home Showplace as an extension of the St. Jude Dream Home® Giveaway Program, to support children battling cancer and other catastrophic diseases. The builder pledged 100% of proceeds from the sale of the home to as a donation for the research hospital.
To view the multimedia release go to:
https://www.multivu.com/players/English/8011654-clayton-summit-homes-st-jude-dream-home-2017/
With the tap of the JOIFUL app, consumers in the Los Angeles area can enjoy mobile salon and spa treatments in the comfort of their home, office or hotel. Beauty industry Artists are at the ready to provide a suite of beauty and wellness treatments including: blowouts; hair styling; men’s haircuts and hot shaves; a variety of massage options; facials; manicures/pedicures as well as specialty services like waxing treatments.
JOIFUL was created to make routine beauty services accessible to time-compressed people who often skip these rituals due to their busy schedules. It’s the only on-demand beauty app with a full suite of salon and spa services – with no look books to limit personal style. Mobile beauty customers can book their treatment, track their Artist in transit and pay with credit card or Apple Pay. Artists will arrive in 60 minutes and gratuity is included in the affordable luxury pricing.
To view the multimedia release go to:
http://www.multivu.com/players/English/8026051-joiful-on-demand-beauty-and-wellness-app/
The Raynaud’s Association, a 501(c)3 non-profit health organization, is launching a new and assertive campaign – “Don’t Turn a Cold Shoulder to Painful Fingers” – to urge those with the painful disorder – and their doctors – not to dismiss the pain Raynaud’s sufferers endure.
October is Raynaud’s Awareness Month, when temperatures generally get chillier and an estimated 5-10 percent of the population experiences numbness and pain in their fingers, toes and other extremities. Stress can also trigger the condition.
To view the multimedia release go to:
https://www.multivu.com/players/English/8396551-raynauds-association-october-raynauds-awareness-month/
Changes in the treatment of pediatric cancer over recent decades have translated to a reduced risk of serious, long-term late health effects of cancer therapy. This is according to the latest analysis from the Childhood Cancer Survivor Study (CCSS), a National Cancer Institute-funded resource for late-effects research, led by investigators at St. Jude Children’s Research Hospital.
“This is the first comprehensive study to demonstrate how changes in treatments over time have impacted the occurrence of late effects experienced by childhood cancer survivors,” said Todd Gibson, Ph.D., assistant member of the Department of Epidemiology and Cancer Control at St. Jude. “We found the 15-year cumulative incidence of people reporting at least one severe health condition decreased from 12.7 percent among childhood cancer survivors diagnosed in the 1970s to 10.1 percent for those diagnosed in the 1980s to 8.8 percent in the 1990s–a statistically significant decline.”
To view the multimedia release go to:
https://www.multivu.com/players/English/7924756-st-jude-childhood-cancer-survivorship-asco-2017/
Studies show that more than two-thirds of aesthetically-oriented consumers are bothered by submental fullness, or “double chin.” And with social media profile images becoming more important than ever, there is interest in looking one’s best.
Submental fullness due to fat beneath the chin can impact a broad range of both men and women and because the condition can be genetic and resistant to diet and exercise. But there’s KYBELLA®, the first and only FDA-approved injectable treatment that is available by prescription only, that has been proven to improve the appearance of moderate to severe fat beneath the chin by physically destroying fat cells in the treatment area. In two pivotal clinical studies for KYBELLA®, reductions in submental fat volume were observed more frequently in the KYBELLA® treated group of 514 patients compared to the placebo group (508 patients) as measured by both clinician and patient ratings. In addition, visual and emotional impacts of submental fat (happy, bothered, self-conscious, embarrassed, looking older or overweight) were evaluated using a 6-question survey and 79% of 1 and 2-grade composite responders reported satisfaction after 12 weeks post final treatment compared with 33.6% of patients who received placebo.
To view the multimedia release go to:
http://www.multivu.com/players/English/7962051-kybella-injectable-double-chin-treatment-campaign/
Inspire Medical Systems, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Inspire Upper Airway Stimulation (UAS) therapy for use in a subset of patients with moderate to severe Obstructive Sleep Apnea (OSA) who are unable to use Continuous Positive Airway Pressure (CPAP). Inspire therapy is a fully implanted neurostimulation device, the first of its kind for sleep apnea, that provides an alternative treatment that is proven, convenient and easy to use.
To view the Multimedia News Release, go to: http://www.multivu.com/mnr/7169651-fda-approves-inspire-upper-airway-stimulation-therapy-sleep-apnea
The public is generally satisfied with cancer research progress over the past 20 years. However, they believe it takes too long for new cancer medicines to reach patients and that their countries invest too little in fighting cancer. Most fear that the current economic crisis will slow cancer research progress. This is according to the PACE Cancer Perception Index: A Six-Nation, Public Opinion Survey of Cancer Knowledge and Attitudes, released today in advance of World Cancer Day, which is recognized on February 4, 2013.
To view Multimedia News Release, go to http://www.multivu.com/mnr/60140-lilly-oncology-pace-cancer-perception-index
